Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
110 hedge funds and large institutions have $255M invested in Paratek Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 46 increasing their positions, 30 reducing their positions, and 16 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 114 → 110 (-4)
20% less call options, than puts
Call options by funds: $2.31M | Put options by funds: $2.9M
21% less capital invested
Capital invested by funds: $324M → $255M (-$68.3M)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$10.8M |
| 2 |
APCM
Arbiter Partners Capital Management
New York
|
+$7.73M |
| 3 |
BlackRock
New York
|
+$6.28M |
| 4 |
AC
Armistice Capital
New York
|
+$6.25M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.2M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$10.7M |
| 3 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
-$6.48M |
| 4 |
BC
Broadfin Capital
New York
|
-$6.21M |
| 5 |
OP
Omni Partners
London,
United Kingdom
|
-$2.01M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
SEI Investments
Oaks,
Pennsylvania
| – | -$3K | -209 | Closed |
|
PRTK Hedge Fund Activity: Q2 2018 in Review
110 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q2 2018, worth a combined $255M — down 21% from $324M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PRTK and 12 opened new positions — a net loss of 4 holders — while 30 trimmed existing stakes and 46 added.
The largest buyer was Highland Capital Management (Texas), adding an estimated $10.8M. The largest seller was Fidelity Investments, exiting entirely with an estimated $16.2M sold.
- 110 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q2 2018, down from 114 in Q1 2018.
- Funds reported $255M of Paratek Pharmaceuticals, Inc. stock for Q2 2018, down 21% quarter-over-quarter.
- 12 funds opened new Paratek Pharmaceuticals, Inc. positions in Q2 2018 and 16 closed out, a net change of -4 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q2 2018 was Highland Capital Management (Texas), an estimated $10.8M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q2 2018 was Fidelity Investments, an estimated $16.2M sold.
Based on aggregated 13F filings for Q2 2018.